Vir Biotechnology Inc (OQ:VIR)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 1800 OWENS STREET, SUITE 900
SAN FRANCISCO CA 94158
Tel: N/A
Website: https://www.vir.bio
IR: See website
<
Key People
Marianne De Backer
Chief Executive Officer, Director
Sung H. Lee
Chief Financial Officer, Executive Vice President
Ann M. Hanly
Executive Vice President, Chief Technology Officer
Steven Rice
Executive Vice President, Chief Administrative Officer
Jennifer Towne
Executive Vice President, Chief Scientific Officer
Jeff Calcagno
Executive Vice President and Chief Business Officer
Sasha Damouni Ellis
Executive Vice President and Chief Corporate Affairs Officer
Phil Pang
Executive Vice President, Chief Medical Officer, Interim Head of Research
 
Business Overview
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Financial Overview
For the fiscal year ended 31 December 2023, Vir Biotechnology Inc revenues decreased 95% to $86.2M. Net loss totaled $615.1M vs. income of $515.8M. Revenues reflect Collaboration revenue decrease of 98% to $37.3M, Contract revenue decrease of 96% to $2.2M, License revenue from a related party decrease from $22.3M to $0K. Net loss reflects Research and development increase of 25% to $526.4M (expense).
Employees: 587 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $86.18M as of Dec 31, 2023
EBITDA (TTM): -$651.85M as of Dec 31, 2023
Net annual income (TTM): -$615.06M as of Dec 31, 2023
Free cash flow (TTM): -$800.36M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 135,032,268 as of Feb 16, 2024
Index Membership: S&P 600 Small Cap
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.